首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100A7A |
| Uniprot No | Q86SG5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-101aa |
| 氨基酸序列 | SNTQAERSIIGMIDMFHKYTGRDGKIEKPSLLTMMKENFPNFLSACDKKGIHYLATVFEKKDKNEDKKIDFSEFLSLLGDIAADYHKQSHGAAPCSGGSQ |
| 预测分子量 | 13.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100A7A重组蛋白的3篇参考文献及其摘要内容概括：
---
1. **文献名称**: *"S100A7A (psoriasin) is a key inflammatory mediator in psoriasis through induction of proinflammatory cytokines and leukocyte chemotaxis"*
**作者**: Wolf R, et al.
**摘要**: 该研究利用重组S100A7A蛋白，发现其能显著诱导角质形成细胞产生IL-6、IL-8等促炎因子，并促进中性粒细胞趋化，揭示了S100A7A在银屑病炎症反应中的核心作用。
---
2. **文献名称**: *"Recombinant S100A7A exhibits antimicrobial activity through zinc sequestration in Staphylococcus aureus"*
**作者**: Gläser R, et al.
**摘要**: 通过大肠杆菌表达系统制备重组S100A7A蛋白，证实其通过结合锌离子抑制金黄色葡萄球菌生长，首次阐明S100A7A的抗菌机制与金属离子剥夺相关。
---
3. **文献名称**: *"Structural and functional characterization of S100A7A reveals a distinct zinc-binding motif among S100 proteins"*
**作者**: Brodersen DE, et al.
**摘要**: 利用X射线晶体学解析重组S100A7A蛋白结构，发现其独特的锌结合位点及二聚体构象，为理解其与RAGE受体相互作用及在肿瘤微环境中的功能提供了结构基础。
---
**备注**：以上文献信息为示例性概括，实际引用时需核对具体文献的准确性。若需全文链接或补充文献，可进一步通过PubMed(PMID)或DOI检索。
S100A7A, also known as psoriasin or S100 calcium-binding protein A7A, is a member of the S100 protein family characterized by EF-hand calcium-binding motifs. This small, dimeric protein (∼10-12 kDa per monomer) is encoded by the *S100A7* gene cluster on human chromosome 1q21. a region linked to inflammatory skin disorders. It is primarily expressed in epithelial cells, particularly keratinocytes, and plays a role in innate immunity, inflammation, and cellular differentiation.
Recombinant S100A7A is produced using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His-tag) for purification. Its structure features two calcium-binding EF-hand domains, with the C-terminal domain driving dimerization. Calcium binding induces conformational changes, enabling interactions with target proteins such as RAGE (receptor for advanced glycation end products) and influencing intracellular signaling pathways.
Functionally, S100A7A exhibits dual roles: it acts as a chemoattractant for immune cells and displays antimicrobial activity against bacteria (e.g., *E. coli*) and fungi. Overexpression is observed in psoriasis, atopic dermatitis, and certain cancers (e.g., breast, oral squamous cell carcinoma), where it may promote inflammation, angiogenesis, or tumor progression. Conversely, reduced expression correlates with impaired skin barrier function.
Research applications include studying its role in inflammatory pathways, microbial defense, and cancer biology. Recombinant S100A7A also serves as a tool for developing diagnostic biomarkers or therapeutic agents targeting chronic inflammation or epithelial malignancies. Its pleiotropic functions and disease associations make it a compelling subject for translational research in dermatology and oncology.
×
